---
title: "Nektar Therapeutics (NKTR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NKTR.US.md"
symbol: "NKTR.US"
name: "Nektar Therapeutics"
industry: "Pharmaceuticals"
datetime: "2026-06-13T14:57:37.178Z"
locales:
  - [en](https://longbridge.com/en/quote/NKTR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NKTR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NKTR.US.md)
---

# Nektar Therapeutics (NKTR.US)

## Company Overview

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.nektar.com](https://www.nektar.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-13T04:30:12.000Z

**Overall: D (0.63)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 129 / 196 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -36.24% |  |
| Net Profit YoY | -18.83% |  |
| P/B Ratio | 3.48 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2006214580.16 |  |
| Revenue | 55633000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -53.60% | E |
| Profit Margin | -284.18% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | -36.24% | E |
| Net Profit YoY | -18.83% | D |
| Total Assets YoY | 197.87% | A |
| Net Assets YoY | 4094.32% | A |
| Cash Flow Margin | 128.88% | B |
| OCF YoY | -36.24% | E |
| Turnover | 0.11 | E |
| Gearing Ratio | 24.51% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Nektar Therapeutics",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-36.24%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-18.83%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.48",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2006214580.16",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "55633000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-53.60%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-284.18%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-36.24%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-18.83%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "197.87%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "4094.32%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "128.88%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-36.24%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.11",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "24.51%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -12.69 | 196/196 | - | - | - |
| PB | 3.48 | 123/196 | 28.27 | 15.70 | 8.75 |
| PS (TTM) | 36.06 | 134/196 | 36.86 | 15.13 | 7.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-04T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 80% |
| Overweight | 1 | 10% |
| Hold | 1 | 10% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 59.38 |
| Highest Target | 192.00 |
| Lowest Target | 80.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/NKTR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/NKTR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/NKTR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/NKTR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**